Dr. Thompson has served as a member of our board of directors since October 2023. Dr. Thompson is currently Executive Vice President of Research and Development, Rare Disease at Amgen. At the time of its acquisition by Amgen, Dr. Thompson served as the Executive Vice President of Research and Development of Horizon Therapeutics. During her time at Horizon, Dr. Thompson played an important role in the transformation of Horizon into a science-based biopharma company, establishing and growing an R&D function comprising scientists and technical experts across research, translational sciences, clinical development, clinical operations, biometrics, PV and safety, regulatory affairs, project and program management, R&D strategy and external innovation. She also played a key role in the acquisition and integration of Viela Bio as well as the expedited filing and approval of TEPEZZA®, including its successful FDA Advisory Committee meeting. Prior to Horizon, Dr. Thompson held roles of increasing seniority and scope at AbbVie, Raptor, InterMune and Amgen in a career spanning clinical development, business development and medical communications. Dr. Thompson has served as a member of the board of California Life Sciences, a life sciences membership organization and was named to the PharmaVoice 100 list in 2023 and the Healthcare Businesswomen’s Association Luminary list in 2021. Dr. Thompson received a Ph.D. in Macromolecular and Cellular Structure and Chemistry from the Scripps Research Institute and a B.S. in Chemistry from Harvey Mudd College.